vs

Side-by-side financial comparison of Clean Energy Fuels Corp. (CLNE) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

CATALYST PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($152.6M vs $112.3M, roughly 1.4× Clean Energy Fuels Corp.). CATALYST PHARMACEUTICALS, INC. runs the higher net margin — 34.5% vs -38.3%, a 72.8% gap on every dollar of revenue. On growth, CATALYST PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (7.6% vs 2.7%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $6.5M). Over the past eight quarters, CATALYST PHARMACEUTICALS, INC.'s revenue compounded faster (24.5% CAGR vs 4.1%).

Bloom Energy is an American public company that designs and manufactures solid oxide fuel cells (SOFCs) which independently produce electricity onsite for power generation in data centers, manufacturing, and other commercial sectors. Founded in 2001 and headquartered in San Jose, California; its fuel cell technology generates electricity through a chemical conversion process, which differs from most other power sources reliant on combustion, and can use natural gas, biogas or hydrogen as fuel...

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CLNE vs CPRX — Head-to-Head

Bigger by revenue
CPRX
CPRX
1.4× larger
CPRX
$152.6M
$112.3M
CLNE
Growing faster (revenue YoY)
CPRX
CPRX
+4.9% gap
CPRX
7.6%
2.7%
CLNE
Higher net margin
CPRX
CPRX
72.8% more per $
CPRX
34.5%
-38.3%
CLNE
More free cash flow
CPRX
CPRX
$38.4M more FCF
CPRX
$44.9M
$6.5M
CLNE
Faster 2-yr revenue CAGR
CPRX
CPRX
Annualised
CPRX
24.5%
4.1%
CLNE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLNE
CLNE
CPRX
CPRX
Revenue
$112.3M
$152.6M
Net Profit
$-43.0M
$52.7M
Gross Margin
82.9%
Operating Margin
-9.5%
40.5%
Net Margin
-38.3%
34.5%
Revenue YoY
2.7%
7.6%
Net Profit YoY
-42.6%
-5.8%
EPS (diluted)
$-0.21
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLNE
CLNE
CPRX
CPRX
Q4 25
$112.3M
$152.6M
Q3 25
$106.1M
$148.4M
Q2 25
$102.6M
$146.6M
Q1 25
$103.8M
$141.4M
Q4 24
$109.3M
$141.8M
Q3 24
$104.9M
$128.7M
Q2 24
$98.0M
$122.7M
Q1 24
$103.7M
$98.5M
Net Profit
CLNE
CLNE
CPRX
CPRX
Q4 25
$-43.0M
$52.7M
Q3 25
$-23.8M
$52.8M
Q2 25
$-20.2M
$52.1M
Q1 25
$-135.0M
$56.7M
Q4 24
$-30.2M
$55.9M
Q3 24
$-18.2M
$43.9M
Q2 24
$-16.3M
$40.8M
Q1 24
$-18.4M
$23.3M
Gross Margin
CLNE
CLNE
CPRX
CPRX
Q4 25
82.9%
Q3 25
84.7%
Q2 25
85.9%
Q1 25
87.3%
Q4 24
84.7%
Q3 24
85.0%
Q2 24
87.4%
Q1 24
87.3%
Operating Margin
CLNE
CLNE
CPRX
CPRX
Q4 25
-9.5%
40.5%
Q3 25
-12.8%
44.7%
Q2 25
-9.0%
45.2%
Q1 25
-121.7%
44.8%
Q4 24
-11.8%
44.3%
Q3 24
-8.1%
39.6%
Q2 24
-5.7%
44.2%
Q1 24
-9.0%
27.5%
Net Margin
CLNE
CLNE
CPRX
CPRX
Q4 25
-38.3%
34.5%
Q3 25
-22.4%
35.6%
Q2 25
-19.7%
35.6%
Q1 25
-130.1%
40.1%
Q4 24
-27.6%
39.4%
Q3 24
-17.3%
34.1%
Q2 24
-16.6%
33.2%
Q1 24
-17.8%
23.6%
EPS (diluted)
CLNE
CLNE
CPRX
CPRX
Q4 25
$-0.21
$0.40
Q3 25
$-0.11
$0.42
Q2 25
$-0.09
$0.41
Q1 25
$-0.60
$0.45
Q4 24
$-0.14
$0.44
Q3 24
$-0.08
$0.35
Q2 24
$-0.07
$0.33
Q1 24
$-0.08
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLNE
CLNE
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$156.1M
$709.2M
Total DebtLower is stronger
$226.8M
Stockholders' EquityBook value
$559.4M
$954.3M
Total Assets
$1.1B
$1.1B
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLNE
CLNE
CPRX
CPRX
Q4 25
$156.1M
$709.2M
Q3 25
$232.2M
$689.9M
Q2 25
$240.8M
$652.8M
Q1 25
$226.6M
$580.7M
Q4 24
$217.5M
$517.6M
Q3 24
$243.5M
$442.3M
Q2 24
$249.3M
$375.7M
Q1 24
$248.9M
$310.4M
Total Debt
CLNE
CLNE
CPRX
CPRX
Q4 25
$226.8M
Q3 25
$284.3M
Q2 25
$277.9M
Q1 25
$271.6M
Q4 24
$265.4M
Q3 24
$264.1M
Q2 24
$263.0M
Q1 24
$262.0M
Stockholders' Equity
CLNE
CLNE
CPRX
CPRX
Q4 25
$559.4M
$954.3M
Q3 25
$585.2M
$920.2M
Q2 25
$590.8M
$856.0M
Q1 25
$596.7M
$794.3M
Q4 24
$713.3M
$727.6M
Q3 24
$724.8M
$660.9M
Q2 24
$723.0M
$608.7M
Q1 24
$722.9M
$561.4M
Total Assets
CLNE
CLNE
CPRX
CPRX
Q4 25
$1.1B
$1.1B
Q3 25
$1.1B
$1.1B
Q2 25
$1.1B
$971.9M
Q1 25
$1.1B
$908.9M
Q4 24
$1.2B
$851.4M
Q3 24
$1.2B
$772.0M
Q2 24
$1.2B
$706.4M
Q1 24
$1.2B
$646.7M
Debt / Equity
CLNE
CLNE
CPRX
CPRX
Q4 25
0.41×
Q3 25
0.49×
Q2 25
0.47×
Q1 25
0.46×
Q4 24
0.37×
Q3 24
0.36×
Q2 24
0.36×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLNE
CLNE
CPRX
CPRX
Operating Cash FlowLast quarter
$13.1M
$44.9M
Free Cash FlowOCF − Capex
$6.5M
$44.9M
FCF MarginFCF / Revenue
5.8%
29.4%
Capex IntensityCapex / Revenue
5.9%
0.0%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$59.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLNE
CLNE
CPRX
CPRX
Q4 25
$13.1M
$44.9M
Q3 25
$13.1M
$32.4M
Q2 25
$35.9M
$71.3M
Q1 25
$23.4M
$60.0M
Q4 24
$21.9M
$70.9M
Q3 24
$21.4M
$72.9M
Q2 24
$18.8M
$64.1M
Q1 24
$2.6M
$31.9M
Free Cash Flow
CLNE
CLNE
CPRX
CPRX
Q4 25
$6.5M
$44.9M
Q3 25
$6.5M
Q2 25
$30.9M
$71.3M
Q1 25
$15.9M
Q4 24
$10.3M
$70.8M
Q3 24
$42.0K
$72.6M
Q2 24
$4.8M
$64.1M
Q1 24
$-15.6M
$31.7M
FCF Margin
CLNE
CLNE
CPRX
CPRX
Q4 25
5.8%
29.4%
Q3 25
6.1%
Q2 25
30.2%
48.6%
Q1 25
15.4%
Q4 24
9.5%
49.9%
Q3 24
0.0%
56.4%
Q2 24
4.9%
52.3%
Q1 24
-15.1%
32.2%
Capex Intensity
CLNE
CLNE
CPRX
CPRX
Q4 25
5.9%
0.0%
Q3 25
6.2%
0.0%
Q2 25
4.8%
0.0%
Q1 25
7.2%
0.0%
Q4 24
10.5%
0.1%
Q3 24
20.3%
0.2%
Q2 24
14.2%
0.0%
Q1 24
17.6%
0.2%
Cash Conversion
CLNE
CLNE
CPRX
CPRX
Q4 25
0.85×
Q3 25
0.61×
Q2 25
1.37×
Q1 25
1.06×
Q4 24
1.27×
Q3 24
1.66×
Q2 24
1.57×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLNE
CLNE

Volume Related Fuel Sales$73.6M66%
Services$15.1M13%
Station Construction Sales$10.7M9%
Volume Related Renewable Identification Number Credits$9.5M8%
Volume Related Low Carbon Fuel Standard Credits$3.4M3%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons